Cost-effectiveness of treatments for diabetic macular oedema: should we pay more attention to the appraisal and reporting of economic evaluations?

Br J Ophthalmol. 2014 Apr;98(4):421-2. doi: 10.1136/bjophthalmol-2013-303352. Epub 2013 Jun 20.

Authors

Gianni Virgili¹, Mariacristina Parravano, Francesca Menchini, Massimo Brunetti

Affiliation

¹ Department of Ophthalmology, Careggi Hospital Eye Clinic, University of Florence, , Florence, Italy.

PMID: 23786886
DOI: 10.1136/bjophthalmol-2013-303352

No abstract available

Keywords: Retina.

Publication types

Editorial

MeSH terms

Angiogenesis Inhibitors / economics*
Cost-Benefit Analysis
Diabetic Retinopathy / drug therapy
Diabetic Retinopathy / economics*
Health Status
Humans
Macular Edema / drug therapy
Macular Edema / economics*
Outcome Assessment, Health Care
Value of Life*

Substances

Angiogenesis Inhibitors